Epigenetic modulators as therapeutic targets in prostate cancer
Epigenetic modulators as therapeutic targets in prostate cancer
Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
1-24
Graça, Inês
0599b318-c389-4035-9087-85d17b3c2c00
Pereira-Silva, Eva
476e8c1a-5057-4c5c-be1e-a70782517ab6
Henrique, Rui
f1f8be24-471e-4266-b8d5-2b96ed2c5ff9
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Jerónimo, Carmen
01418979-1230-48c4-a15d-341b3cc4063c
Graça, Inês
0599b318-c389-4035-9087-85d17b3c2c00
Pereira-Silva, Eva
476e8c1a-5057-4c5c-be1e-a70782517ab6
Henrique, Rui
f1f8be24-471e-4266-b8d5-2b96ed2c5ff9
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Jerónimo, Carmen
01418979-1230-48c4-a15d-341b3cc4063c
Graça, Inês, Pereira-Silva, Eva, Henrique, Rui, Packham, Graham, Crabb, Simon J. and Jerónimo, Carmen
(2016)
Epigenetic modulators as therapeutic targets in prostate cancer.
Clinical Epigenetics, 8 (98), .
(doi:10.1186/s13148-016-0264-8).
(PMID:27651838)
Abstract
Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
Text
__soton.ac.uk_ude_personalfiles_users_sjc7_mydesktop_art%3A10.1186%2Fs13148-016-0264-8.pdf
- Version of Record
More information
Accepted/In Press date: 7 September 2016
e-pub ahead of print date: 15 September 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 400909
URI: http://eprints.soton.ac.uk/id/eprint/400909
ISSN: 1868-7075
PURE UUID: b2964e3c-2af6-4b7a-b5b8-4ebfd9a1b683
Catalogue record
Date deposited: 30 Sep 2016 08:24
Last modified: 15 Mar 2024 03:16
Export record
Altmetrics
Contributors
Author:
Inês Graça
Author:
Eva Pereira-Silva
Author:
Rui Henrique
Author:
Carmen Jerónimo
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
